The certification of rules regarding medical-loss ratios brings some clarity to an issue that has tried the patience of health plans, but now the hard work begins, according to analysts.
NATIONAL REPORTS-The certification of rules regarding medical-loss ratios brings some clarity to an issue that has tried the patience of health plans, but now the hard work begins, analysts say.
"The legislation does result in greater transparency into company operations," says Nancy L. Litwinski, director, National Healthcare for Deloitte & Touche LLP. "It's an opportunity to regain public trust and confidence that's often misplaced."
Although the rules have been certified by the U.S. Department of Health and Human Services, the fallout remains unclear, including how insurers will account for spending at least 85% of premiums on health services for groups of 100 or more and 80% for smaller groups and individuals.
Historically, insurance companies have profited more from the small group market, but increased scrutiny of MLR likely will mean reduced net incomes in that segment.
Insurers face challenges on both sides of the MLR equation, justifying medical claims expenses through quality initiatives while holding down costs on the administrative side. Broker or agent commissions are specifically classified as nonclaim costs, for example. Even smaller insurers will have to re-examine overhead costs, distribution and marketing expenses to maintain profits under the new guidelines.
"Companies will need to look at these items and try and become more efficient in the delivery of those services," Litwinski says. "Retaining as much of that 20% as possible to remain profitable will come through efficiency."
Upended: Can PBM Transparency Succeed?
March 6th 2024Simmering tensions in the pharmacy benefit management (PBM) industry have turned into fault lines. The PBMs challenging the "big three" have formed a trade association. Purchaser coalitions want change. The head of the industry's trade group says inherent marketplace friction has spilled over into political friction.
Read More
In this episode of the "Meet the Board" podcast series, Briana Contreras, Managed Healthcare Executive editor, speaks with Ateev Mehrotra, a member of the MHE editorial advisory board and a professor of healthcare policy and medicine at Harvard Medical School. Mehtrotra is also a hospitalist at the Beth Israel Deaconess Medical Center in Boston. In the discussion, Contreras gets to know Mehrotra more on a personal level and picks his brain on some of his research interests including telehealth, alternative payment models and price transparency.
Listen
Inflation Reduction Act: Reforms to Patient Cost-Sharing
September 18th 2023Lower out-of-pocket costs for patients might put upward pressure on drug prices, as manufacturers face less price sensitivity, note Matthew Majewski and Rhett Johnson of Charles River Associates. But they also note that upward pressure on price is likely to be limited to the inflation rate as any additional price increase would need to be paid back to CMS in the form of inflation rebates.
Read More
Spending climbed by 2.7% in 2021. In 2020, it soared by 10.3%, fueled by federal government spending in response to the pandemic. The blizzard of calculations of 2021 healthcare spending by CMS’ actuaries also provides further evidence that utilization of healthcare services bounced back in 2021.
Read More